Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa.
CD4 and viral load data
National Health Laboratory Service
South Africa
community-based clinics
patient transfers
retention in care
transfer of HIV care
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
25
07
2018
accepted:
22
05
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
14
4
2020
Statut:
ppublish
Résumé
Changes to the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) funding have led to closures of non-governmental HIV clinics with patient transfers to government-funded clinics. We sought to determine the success of transfers in South Africa using a national data source. All adults (≥18 years) on antiretroviral therapy (ART) who visited a single PEPFAR-funded hospital-based HIV clinic in Durban, South Africa from March to June 2012 were transferred to community-based clinics. Previously, we matched patient records from the hospital-based HIV clinic with National Health Laboratory Services (NHLS) Corporate Data Warehouse (CDW) data to estimate the proportion of patients with a CD4 count or viral load (VL) in the CDW during the year before transfer. As a proxy for retention in care, in this study we evaluated whether patients had a CD4 count or VL at another facility within approximately three years of transfer. Patients referred to a private doctor at transfer were excluded from the analysis. We assessed predictors (age, sex, CD4 count, VL status, ART duration and location of future care) of not having post-transfer laboratory data using Cox proportional hazards models. Of the 3893 patients referred to a government facility at transfer, 41% were male and median age was 39 years (IQR 34 to 46). There was a post-transfer CD4 count or VL from another facility for 23% of these individuals within six months, 44% within one year, 57% within two years and 61% within approximately three years. Male sex (aHR 1.20, 95% CI 1.10 to 1.31) and shorter duration on ART (<3 months, aHR 3.80, 95% CI 2.77 to 5.21; three months to one year, aHR 1.32, 95% CI 1.15 to 1.51, each compared with >1 year) were associated with not having a post-transfer record. Using data from the NHLS CDW, 61% of patients had evidence of a post-transfer laboratory record at another facility within approximately three years after closure of a large South African HIV clinic. Males and those with shorter time on ART prior to transfer were at highest risk for lacking follow-up laboratory data. As patients transfer care, national data sources can be used to evaluate long-term patient care trajectories.
Identifiants
pubmed: 31243898
doi: 10.1002/jia2.25326
pmc: PMC6595194
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25326Subventions
Organisme : NIMH NIH HHS
ID : R01 MH090326
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH108427
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Informations de copyright
© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
J Int AIDS Soc. 2019 Jun;22(6):e25326
pubmed: 31243898
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25114
pubmed: 30027583
AIDS Care. 2015;27(10):1298-303
pubmed: 26300297
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90
pubmed: 26605986
Int J Cancer. 2016 Sep 15;139(6):1209-16
pubmed: 27098265
Lancet. 2012 Sep 8;380(9845):889-98
pubmed: 22901955
PLoS Med. 2015 Nov 24;12(11):e1001905; discussion e1001905
pubmed: 26599699
J Acquir Immune Defic Syndr. 2010 Mar;53(3):405-11
pubmed: 19745753
BMJ Open. 2018 Aug 23;8(8):e021506
pubmed: 30139898
S Afr Med J. 2014 Mar;104(3 Suppl 1):235-8
pubmed: 24893499
PLoS Med. 2018 Jun 11;15(6):e1002589
pubmed: 29889844
N Engl J Med. 2013 Oct 10;369(15):1385-7
pubmed: 24106930
Open Forum Infect Dis. 2014 Aug 12;1(2):ofu058
pubmed: 25734128
Int J Tuberc Lung Dis. 2015 Jan;19(1):104-10
pubmed: 25519799
PLoS One. 2013;8(2):e55308
pubmed: 23405133
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e64-71
pubmed: 23429504
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e1-12
pubmed: 25942465
AIDS. 2011 Oct 23;25(16):2027-36
pubmed: 21997488
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):383-389
pubmed: 28225717
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e67-75
pubmed: 24977471
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
BMC Health Serv Res. 2014 Aug 18;14:350
pubmed: 25134822
BMC Infect Dis. 2014 Aug 16;14:442
pubmed: 25129689
Lancet Glob Health. 2013 Dec;1(6):e319-20
pubmed: 25104588
Antivir Ther. 2014;19 Suppl 3:105-16
pubmed: 25310359
J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):429-32
pubmed: 21857353
Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44
pubmed: 20820972
Lancet. 2010 Oct 9;376(9748):1244-53
pubmed: 20923715
BMC Health Serv Res. 2010 Aug 05;10:229
pubmed: 20687955
PLoS Med. 2011 Jul;8(7):e1001055
pubmed: 21811402
PLoS Med. 2010 Jun 22;7(6):e1000296
pubmed: 20582324